Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website

Case Report

Volume 13, Number 5, May 2022, pages 240-243

Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series


Table 1. Summary of Three Cases
Case seriesCase 1Case 2Case 3
MMR: mismatch repair expression; PD-L1: programmed death-ligand 1.
Age on diagnosis (years)516335
Clinical stagingBorderline resectableInitially locally advanced and recurrence with metastaticMetastatic
MMR statusDeficient MMR expressionIntact MMR expressionIntact MMR expression
Tumor mutational burden status
  PD-L1 statusNot testedPD-L1 positivePD-L1 positive
TreatmentNeoadjuvant chemotherapy and surgical resectionNeoadjuvant chemotherapy and surgical resection followed by chemoradiationThree different regiments of chemotherapy due to progression
Use of pembrolizumabSingle maintenance therapyCombine with olaparib as maintenance therapyCombine with chemotherapy and olaparib
Follow-up4 years3 years8 months